Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 905681 |
Synonyms | |
Therapy Description |
BI 905681 is an antagonist of lipoprotein receptor-related protein 5 (LRP5), that binds to LRP5 and inhibits the Wnt/beta-catenin signaling pathway, potentially leading to inhibition of tumor cell proliferation and activation of cytotoxic T lymphocytes (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 905681 | BI905681|BI-905681|LRP5 Antagonist BI 905681 | BI 905681 is an antagonist of lipoprotein receptor-related protein 5 (LRP5), that binds to LRP5 and inhibits the Wnt/beta-catenin signaling pathway, potentially leading to inhibition of tumor cell proliferation and activation of cytotoxic T lymphocytes (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04147247 | Phase I | BI 905681 | A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread | Completed | USA | 0 |